– – Brings Deep Transaction Expertise to Expand and Strengthen Cosette’s Branded Pharmaceutical Portfolio – –

Bridgewater, N.J. – March 18, 2026 – Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Joseph (Joe) Skelton as Senior Vice President, Corporate Development and Strategy.

In this role, Joe will lead Cosette’s inorganic growth strategy, overseeing corporate development, and strategic initiatives to expand and strengthen the company’s branded pharmaceutical portfolio. He will report directly to President and CEO Apurva Saraf and partner closely with the executive leadership team to drive long-term enterprise value creation.

“Joe brings a rare combination of deep transaction expertise, strategic judgment, and hands-on operating experience across specialty pharmaceuticals and biotechnology,” said Apurva Saraf, President and CEO, Cosette Pharmaceuticals. “His proven ability to source, structure, and execute complex transactions — while maintaining a disciplined focus on value creation — makes him an ideal leader for Cosette as we continue to scale our portfolio, accelerate growth, and deliver needed medicines for patients.”

Joe brings more than a decade of experience across business development, corporate development, and life sciences investment banking, with completed transaction experience exceeding $9 billion across M&A, licensing, and capital markets. Most recently, he served as Chief Financial Officer of I-Mab Biopharma (now NovaBridge), where he led capital markets strategy, business development initiatives, and operational transformation across the U.S. and Asia. During his tenure, he delivered significant shareholder value through capital optimization, strategic divestitures, and disciplined portfolio management.

Prior to I-Mab, Joe was a Senior Vice President in Life Sciences Investment Banking at Truist Securities, where he advised biotechnology, specialty pharma, and generics companies on M&A and capital formation transactions. Earlier in his career, he held roles at Amneal Pharmaceuticals, where he supported corporate development and inorganic growth initiatives, as well as at Cantor Fitzgerald, Janney Montgomery Scott, and Ernst & Young.

“Cosette has built a leading, high-quality branded portfolio through thoughtful, disciplined execution,” said Joe Skelton, Senior Vice President, Corporate Development and Strategy, Cosette Pharmaceuticals. “I’m thrilled to join the team to further advance Cosette’s growth strategy and deliver important medicines for patients and sustainable, long-term value for partners, and stakeholders.”

Joe holds a Master of Science in Accounting and Information Analysis and a Bachelor of Science in Accounting and Finance from Lehigh University.

About Cosette Pharmaceuticals:

Cosette Pharmaceuticals, Inc. is a U.S.-based, fully integrated pharmaceutical company with a fast-growing portfolio of products in women’s health and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 350+ dedicated team members across all functional areas. Cosette is backed by Avista Healthcare Partners, a healthcare focused private equity firm, and funds managed by Hamilton Lane, a private markets investment management firm (Nasdaq: HLNE). For more information, please visit www.cosettepharma.com or follow Cosette on LinkedIn.

Contacts:
Cosette Pharmaceuticals

Media:
media@cosettepharma.com